AKAP79/150

AKAP79/150
Name	A-kinase anchoring protein 79/150
Organism	Homo sapiens, Rattus norvegicus
Length	~347 aa (human), ~673 aa (rat)
Alias	AKAP79; AKAP150

AKAP79/150 is a member of the A-kinase anchoring protein family that scaffolds signaling enzymes to coordinate synaptic, neuronal, and epithelial responses. First characterized in studies alongside Paul Greengard, Susumu Tonegawa, and Eric Kandel-related paradigms, AKAP79/150 integrates enzymes such as protein kinase A, calcineurin, and protein kinase C at membranes to modulate plasticity and excitability in systems including hippocampal circuits and vascular endothelium.

Introduction

AKAP79/150 was discovered during molecular investigations of subcellular targeting of cAMP-dependent pathways in neurons and epithelia and later linked to electrophysiological work by groups in Harvard University, Cold Spring Harbor Laboratory, and University College London. It serves as a scaffold for PKA regulatory subunit II, calcineurin A, and PKCα at the postsynaptic density and plasma membrane, placing it central to models developed by researchers at Massachusetts Institute of Technology, Stanford University, and the National Institutes of Health. AKAP79/150 research interfaces with methodologies from X-ray crystallography, cryo-electron microscopy, and patch clamp electrophysiology.

Structure and Isoforms

AKAP79/150 comprises modular domains: an N-terminal membrane-targeting region, central kinase/phosphatase binding sites, and C-terminal dimerization motifs identified using approaches from Max Perutz-style structural biology and labs such as European Molecular Biology Laboratory. Isoforms arise from alternative splicing and species differences; the human protein (~347 amino acids) contrasts with the rat isoform (~673 amino acids) characterized in studies at Cold Spring Harbor Laboratory and Johns Hopkins University. Domains map to interaction sites for regulatory subunits of PKA (RII-binding helix), the PxIxIT-like motif for calcineurin recruitment, and polybasic regions that mediate association with phospholipids analyzed in publications affiliated with University of California, San Francisco and University of Oxford.

Cellular Localization and Targeting

AKAP79/150 localizes to postsynaptic densities, dendritic spines, and the plasma membrane, a distribution defined in imaging studies at Columbia University, University of Pennsylvania, and University of Cambridge. Targeting depends on electrostatic interactions with phosphatidylinositol phosphates and palmitoylation motifs explored in labs at Yale University and University of California, Los Angeles. Activity-dependent trafficking to endosomal compartments and recycling pathways has been reported in research from MIT, Salk Institute, and the Max Planck Institute for Brain Research, linking AKAP79/150 localization to mechanisms described by investigators formerly at The Rockefeller University.

Binding Partners and Molecular Interactions

AKAP79/150 binds a network of enzymes and receptors: protein kinase A (RII), calcineurin, protein kinase C, AMPA-type glutamate receptors such as GluA1, NMDA receptors including NR2B, and scaffolds like PSD-95. It interfaces with cytoskeletal regulators investigated by groups at Johns Hopkins University School of Medicine and Vanderbilt University Medical Center, and with membrane organizers characterized by teams at Scripps Research and University of Toronto. Proteomic surveys from Broad Institute and Wellcome Trust Sanger Institute expanded the AKAP79/150 interactome to include ubiquitin machinery studied at Cold Spring Harbor Laboratory and trafficking adaptors defined by work at EMBL-EBI.

Physiological Roles and Signaling Pathways

AKAP79/150 coordinates synaptic plasticity mechanisms underlying long-term potentiation and long-term depression explored in labs at Columbia University, University College London, and Harvard Medical School. It modulates ion channel function including L-type calcium channel regulation investigated by teams at University of California, Davis and University of Texas Southwestern Medical Center, and influences neuronal excitability linked to studies at University of Michigan and University of Washington. In non-neuronal contexts, AKAP79/150 contributes to endothelial barrier function and insulin signaling described by researchers at Imperial College London and University of Copenhagen.

Regulation and Post-translational Modifications

AKAP79/150 is regulated by phosphorylation by kinases such as PKA and PKC and by palmitoylation and ubiquitination identified in experiments conducted at University of Basel and Karolinska Institutet. Activity-dependent dephosphorylation by calcineurin controls its association dynamics in paradigms advanced at National Institute of Mental Health and University of Freiburg. Proteostasis and degradation pathways involving E3 ligases characterized at Cold Spring Harbor Laboratory and University of Göttingen modulate AKAP79/150 protein levels during synaptic remodeling.

Clinical Significance and Disease Associations

Alterations in AKAP79/150 expression or function have been implicated in neurological disorders such as epilepsy, mood disorders, and neurodegeneration, with translational studies at Mayo Clinic, Mount Sinai Hospital, and Massachusetts General Hospital. Links to cardiovascular dysfunction and metabolic disease were explored in cohorts curated at Johns Hopkins Hospital and Cleveland Clinic. Genetic and proteomic association studies reported by consortia including ENCODE, GTEx, and efforts at Broad Institute support investigation of AKAP79/150 as a modifier in complex disease phenotypes examined alongside biomarkers from World Health Organization-supported initiatives.

Category:Scaffold proteins